trending Market Intelligence /marketintelligence/en/news-insights/trending/oup6fgeGuJoy1ikudweuwQ2 content esgSubNav
In This List

Rhythm Pharmaceuticals names former GSK veteran as chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Rhythm Pharmaceuticals names former GSK veteran as chief medical officer

Boston-based Rhythm Pharmaceuticals Inc. said it appointed Murray Stewart as its chief medical officer.

He will join Rhythm Pharmaceuticals from Novelion Therapeutics Inc., where he served as head of research and development. Prior to that, he spent 18 years at GlaxoSmithKline PLC in various roles, including as the chief medical officer of the U.K.-based pharmaceutical giant.

Stewart is expected to help the company advance the development of setmelanotide and RM-853 to treat rare genetic disorders of obesity, Rhythm CEO Keith Gottesdiener said.